Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1185764 | 0.82 | NR3C2 (0.42) | MEN1KMT2AALDH1A1CSF1RGAA | |
| SCHEMBL1299290 | 0.82 | MAPT (0.53) | MEN1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL27721951 | 0.82 | MEN1 (0.53) | MEN1KMT2ABAZ2BBAZ2AALDH1A1 | |
| SCHEMBL2237150 | 0.82 | BAZ2B (0.39) | MEN1KMT2ABAZ2BBAZ2AALDH1A1 | |
| SCHEMBL18414587 | 0.81 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1CSF1RLMNA | |
| Ammonia Solution, Strong SCHEMBL2237158 | 0.81 | MAPT (0.52) | MEN1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL29191080 | 0.79 | ALDH1A1 (0.64) | MEN1KMT2ABAZ2BBAZ2AALDH1A1 | |
| SCHEMBL1663200 | 0.79 | CREBBP (0.54) | MEN1KMT2AALDH1A1CSF1RLMNA | |
| SCHEMBL3348546 | 0.79 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1POLBGAA | |
| SCHEMBL1073975 | 0.78 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1POLBCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2023138412-A1 | FUSED PYRIMIDIN-2-AMINE COMPOUNDS AS CDK20 INHIBITORS | INSILICO MEDICINE IP LIMITED (CN) | 2023-07-27 | — | — | WO | disclosed |
| US-20220308043-A1 | FLUORESCENT PROBES FOR IDENTIFICATION AND QUANTIFICATION OF HEPATIC TRANSPORTERS IN VITRO AND IN VIVO | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-09-29 | — | — | US | disclosed |
| CN-108026105-B | TGF-beta receptor antagonists | 百时美施贵宝公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10336761-B2 | TGFβ receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336761-B2 | TGFβ receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| EP-3325484-A1 | TGF BETA RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2018-05-30 | — | — | EP | disclosed |
| US-6051243-A | USEFUL IN THE TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL CONDITIONS ASSOCIATED WITH A KERATINIZATION DISORDER, DERMATOLOGICAL CONDITIONS (AND THE LIKE) INCLUDING AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 2000-04-18 | — | — | US | disclosed |
| EP-0991417-A1 | COMPLEX FORMATION BETWEEN DSDNA AND OLIGOMER OF HETEROCYCLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0986539-A1 | DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5998140-A | COMPLEXES OF CELL WITH OLIGOMER | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0885189-A2 | METHOD FOR THE SYNTHESIS OF POLY-PYRROLE AND POLY-IMIDAZOLE CARBOXAMIDES ON A SOLID SUPPORT | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998050058-A1 | COMPLEX FORMATION BETWEEN DSDNA AND OLIGOMER OF HETEROCYCLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050582-A1 | COMPLEX FORMATION BETWEEN dsDNA AND OLIGOMER OF HETEROCYCLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998049142-A1 | DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5709867-A | TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, AND OPHTHALMOLOGICAL DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-01-20 | — | — | US | disclosed |
| WO-1997030975-A2 | METHOD FOR THE SYNTHESIS OF POLY-PYRROLE AND POLY-IMIDAZOLE CARBOXAMIDES ON A SOLID SUPPORT | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336761-B2 | TGFβ receptor antagonist | TGFBR2, TGFBR1, SMAD2 | MEN1 3092/4885KMT2A 2468/4885BAZ2B 1746/4885 |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | TGFBR2, TGFBR1, TGFB2 | MEN1 2799/4885KMT2A 2698/4885BAZ2B 2000/4885 |
| US-20220308043-A1 | FLUORESCENT PROBES FOR IDENTIFICATION AND QUANTIFICATION OF HEPATIC TRANSPORTERS IN VITRO AND IN VIVO | ABCB11, SLC10A1, SLC10A2 | MEN1 3014/4885KMT2A 4811/4885BAZ2B 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.